Micromet's cancer drug portfolio draws big drugmakers' attention

06/14/2010 | Bloomberg Businessweek

Biotech firm Micromet was able to secure a partnership with major drugmakers, including Bayer and Boehringer Ingelheim, because of its line of cancer treatments that might boost the effectiveness of rival medicines. Blinatumomab, Micromet's drug candidate for acute lymphocytic leukemia, led to complete remission during a clinical trial in about 80% of patients who still had leukemia cells after undergoing different forms of chemotherapy.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ